<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cerebrospinal fluid (CSF) concentrations of corticotropin, growth hormone, thyrotropin, prolactin, luteinizing hormone, and follicle stimulating hormone were measured in 28 patients with various <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurologic disorders</z:e>, in 49 patients with <z:e sem="disease" ids="C0032019" disease_type="Neoplastic Process" abbrv="">pituitary tumors</z:e> of whom 22 had suprasellar extension, and in 6 patients with <z:mpath ids='MPATH_257'>craniopharyngiomas</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>With the exception of 1 patient with <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e>, CSF adenohypophyseal hormone concentrations were low in patients with neurologic disease and in patients with <z:e sem="disease" ids="C0032019" disease_type="Neoplastic Process" abbrv="">pituitary tumor</z:e> without suprasellar extension </plain></SENT>
<SENT sid="2" pm="."><plain>In marked contrast, 21 to 22 patients with suprasellar extension of a <z:e sem="disease" ids="C0032019" disease_type="Neoplastic Process" abbrv="">pituitary tumor</z:e> and 2 of 6 patients with a <z:mpath ids='MPATH_257'>craniopharyngioma</z:mpath> had elevations of one or more CSF adenohypophyseal hormones </plain></SENT>
<SENT sid="3" pm="."><plain>Posttreatment CSF adenohypophyseal hormone levels fell from previously elevated levels in 4 of 5 patients </plain></SENT>
<SENT sid="4" pm="."><plain>These data suggest that an elevated CSF adenohypophyseal hormone concentration is a sensitive indicator of suprasellar extension of a <z:e sem="disease" ids="C0032019" disease_type="Neoplastic Process" abbrv="">pituitary tumor</z:e>, and posttreatment measurements are useful in determining efficacy of therapy </plain></SENT>
</text></document>